文献速递认知障碍与痴呆

阿尔茨海默病与轻度认知障碍中的2期无效性试验:ADNI数据集的队列分析

Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.
PubMed 文献 · Neurology · 2026-06-18

本研究利用ADNI队列数据评估在阿尔茨海默病(AD)相关痴呆和轻度认知障碍(MCI)中开展Simon两阶段无效性试验的可行性。结果显示,CDR-SB是监测认知衰退的最优主要结局,AD相关痴呆的短期试验可行,而MCI试验需更长时间和特定入组标准。

要点

  • CDR-SB在AD相关痴呆和MCI中显示最大衰退百分比,12个月时60.6%恶化(≥1.0分)而仅6.2%改善。
  • AD相关痴呆的短期(6-12个月)无效性试验可行,样本量35-62例;MCI试验需24个月及基于年龄、APOE ε4和基线CDR-SB的入组标准。
  • 无效性试验为AD相关痴呆提供更快、成本更低的2期试验替代方案,但需在临床试验数据集中进一步验证。

核心结论

  • 在AD相关痴呆中开展无效性试验可行,CDR-SB似乎是最优主要结局。

研究设计与样本

  • 基于ADNI前瞻性队列的纵向数据分析,纳入2665名参与者(平均年龄73.4岁,女性1260名,AD相关痴呆424例)。

主要发现

  • AD相关痴呆中,CDR-SB在12个月时60.6%患者恶化≥1.0分,6.2%改善;ADAS-Cog 13恶化≥5分者41.7%,改善者5.8%;MMSE恶化≥5分者25.8%,改善者2.9%。
  • CDR-SB在AD相关痴呆和MCI中显示最大衰退百分比。
  • AD相关痴呆的短期试验(6-12个月)样本量35-62例可行;MCI试验需24个月及特定入组标准。

关键数值与推荐

  • CDR-SB恶化阈值≥1.0分(12个月);ADAS-Cog 13恶化阈值≥5分(12个月);MMSE恶化阈值≥5分(12个月)。
  • MCI试验入组标准需考虑年龄、载脂蛋白E ε4状态和基线CDR-SB表现。

临床怎么用

  • 在AD相关痴呆的2期试验中,可考虑采用Simon两阶段无效性设计,以CDR-SB为主要结局,缩短试验周期并降低成本。
  • 针对MCI人群设计无效性试验时,需设定24个月随访,并依据年龄、APOE ε4状态和基线CDR-SB表现筛选受试者。

局限性

  • 结果需在临床试验数据集中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The cost and complexity of phase 2 randomized-controlled trials (RCTs) hinder further development of promising treatment candidates for Alzheimer disease (AD). The Simon Two-Stage futility trial design, originally developed for oncology, offers a streamlined approach to evaluate potential disease-modifying therapies by comparing single-arm outcomes with historical controls, but is predicated on identifying outcome measures that reliably worsen with the natural history of the disease, with minimal risk of improvement. We sought to determine the feasibility of such futility trials in AD-associated dementia and mild cognitive impairment (MCI) using a large prospective cohort. METHODS: We analyzed longitudinal data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cognitive decline was assessed using AD Assessment Scale-Cognitive Subscale (ADAS-Cog 11 and ADAS-Cog 13), Clinical Dementia Rating-Sum of Boxes (CDR-SB), and Mini-Mental State Examination (MMSE) at 6, 12, and 24 months using different thresholds for worsening vs improvement. Binary logistic regression models examined baseline factors associated with cognitive worsening using different thresholds of worsening for each outcome of interest to assess what additional selection criteria may be needed for futility trials in AD-associated dementia vs MCI. Sample size estimates were derived based on expected rates of decline. RESULTS: Among 2,665 participants (mean age 73.4 years [SD: 7.5], 1,260 [47.3%] female, 424 with AD-associated dementia), the CDR-SB exhibited the largest percentage of decline in AD-associated dementia and MCI, with 60.6% of patients with AD-associated dementia showing worsening when using a threshold of ≥1.0 points at 12 months vs 6.2% showing improvement. ADAS-Cog 11 and 13 showed similar decline patterns; for example, 41.7% with AD-associated dementia worsened by ≥ 5 points at 12 months on ADAS-Cog 13, whereas 5.8% improved. MMSE exhibited lower sensitivity; 25.8% with AD-associated dementia worsened by ≥ 5 points at 12 months, whereas 2.9% improved. Shorter trials (6-12 months) with 35-62 participants seemed feasible in AD-associated dementia, whereas MCI trials seemed to require 24 months and specific entry criteria based on age, apolipoprotein E ε4 status, and baseline CDR-SB performance. DISCUSSION: Futility trials seem feasible in AD-associated dementia, offering a faster, cost-effective alternative to traditional phase 2 RCTs. CDR-SB seems to be the optimal primary outcome. Further validation in clinical trial data sets is warranted.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ganesh A, Smith EE, Mostert J, et al. Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set. Neurology. 2026. PMID: 42314102. doi:10.1212/WNL.0000000000218227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。